Youxun Medical completes hundreds of millions of financing

Recently, Youxun Medical announced the completion of a new round of equity financing. This round was led by Decheng Capital, Infinity Capital, Meinian Great Health Industry Fund, Beijing Zhongguancun Science City Company, Shandong Hongqiao Capital, Hongzhou Capital and Hengjia Capital participated in the investment, with a total of RMB 100 million. Previously, Uxun Medical has obtained strategic investment from BGI and early investment from investment institutions such as Xianfeng Qiyun and CITIC Guoan. The funds from this round of financing will be mainly used for the research and development, registration application and industrialization of Youxun Medical’s innovative instruments and reagent products, accelerate the layout and expansion of the national marketing network, and further consolidate Youxun in the field of liquid biopsy and women’s health early screening. The leading position of technological innovation and industrial incubation.

Youxun Medical was established in 2015 as a national high-tech industrial unit and a national-level specialized and special new “little giant” enterprise (the first batch of the first year). It has successively undertaken the “13th Five-Year Plan” reproductive health and major birth Defect prevention and control special project and tumor liquid biopsy multi-center R&D project. After nearly 7 years of precipitation, Youxun Medical has built a medical technology product and service platform integrating R&D incubation, clinical application, as well as in vitro diagnostic reagents and supporting instruments, and has several advanced product lines. The Youxun Medical Laboratory under the group has 3,000 square meters of high-standard clinical molecular testing and gene sequencing central laboratory and information analysis center; Youxun Medical Devices has high-standard medical services based on NGS, QPCR and POCT platforms in Beijing and Hangzhou. Equipment, in vitro diagnostic reagent research and development center and GMP production base.